Our top pick for
Guardant Health Inc is a diagnostics & research business based in the US. Guardant Health shares (GH) are listed on the NASDAQ and all prices are listed in US Dollars. Guardant Health employs 864 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$99.44|
|52-week range||$96.66 - $180.83|
|50-day moving average||$120.84|
|200-day moving average||$124.89|
|Wall St. target price||$167.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.77|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-12)||-3.99%|
|1 month (2021-09-17)||-24.70%|
|3 months (2021-07-19)||-14.89%|
|6 months (2021-04-19)||-34.97%|
|1 year (2020-10-19)||-3.21%|
|2 years (2019-10-18)||52.35%|
|3 years (2018-10-19)||177.84%|
|5 years (2016-10-15)||N/A|
|Revenue TTM||$323.7 million|
|Gross profit TTM||$194.2 million|
|Return on assets TTM||-12.65%|
|Return on equity TTM||-36.74%|
|Market capitalisation||$10.3 billion|
TTM: trailing 12 months
There are currently 4.6 million Guardant Health shares held short by investors – that's known as Guardant Health's "short interest". This figure is 7.2% up from 4.3 million last month.
There are a few different ways that this level of interest in shorting Guardant Health shares can be evaluated.
Guardant Health's "short interest ratio" (SIR) is the quantity of Guardant Health shares currently shorted divided by the average quantity of Guardant Health shares traded daily (recently around 741462.98076923). Guardant Health's SIR currently stands at 6.24. In other words for every 100,000 Guardant Health shares traded daily on the market, roughly 6240 shares are currently held short.
However Guardant Health's short interest can also be evaluated against the total number of Guardant Health shares, or, against the total number of tradable Guardant Health shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Guardant Health's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Guardant Health shares in existence, roughly 50 shares are currently held short) or 0.0478% of the tradable shares (for every 100,000 tradable Guardant Health shares, roughly 48 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Guardant Health.
Find out more about how you can short Guardant Health stock.
We're not expecting Guardant Health to pay a dividend over the next 12 months.
Over the last 12 months, Guardant Health's shares have ranged in value from as little as $96.66 up to $180.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Guardant Health's is 0.526. This would suggest that Guardant Health's shares are less volatile than average (for this exchange).
Guardant Health, Inc. , a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.